a2 Milk tips $2b revenue but China still carries it

a2 Milk tips b revenue but China still carries it

Summary

The a2 Milk Company told its annual meeting it expects FY27 revenue to top $2 billion, reaching a medium-term target it narrowly missed a year earlier. FY26 revenue was $1.97b, up 12.4 percent, but net profit after tax fell 5.8 percent to $207.5 million. Chief executive David Bortolussi said the company "just fell short" of $2b and expects to hit it this year.

FY27 guidance is for mid-single-digit revenue growth, weighted to the second half, with first-half revenue slightly lower and underlying earnings "significantly down"; the full-year underlying EBITDA margin is expected to be around 15 percent, including about $15m in one-off Pokeno transition costs and about $70m in capital expenditure. The problems began in the fourth quarter of FY26: freight issues, production backlogs at Synlait, longer product release times and increased Chinese customs and testing requirements left shelves empty and consumers switched to other brands. China-label infant formula revenue fell 14.0 percent to $544.3m for the year, as 6.5 percent growth in the first half was offset by a 33.0 percent slump in the second.

China-label shipments have recovered to about 50 percent of pre-disruption levels, up from about 40 percent in August. Management has kept distribution at about two-thirds of previous levels to protect retail sell-through and avoid excess inventory. The company's growth path shows that from $1.21b in FY21 to about $2b in FY27, China-label formula contributes $400m of growth, English-label formula $300m, other China nutritionals $200m, and emerging markets, Australia and New Zealand, and the US $100m each.

The total China-label market value fell 0.2 percent in FY26, but A2 protein grew 7 percent to account for 22 percent of the category, with the top five brands holding 59 percent of market value. Vietnam is a bright spot, with distribution covering more than 3,500 stores and second-half sales up 128 percent, followed by the Philippines, Singapore, Malaysia, Indonesia, the UAE and Saudi Arabia.

Commentary

China remains the key variable behind a2 Milk's $2b revenue target. China-label infant formula revenue fell 14 percent in FY26, including a 33 percent plunge in the second half, directly dragging on the full-year result. Although the company expects FY27 revenue to top $2b, growth relies mainly on China-label products contributing $400m — more than the emerging markets combined.

For New Zealand small and medium business owners, a2's difficulties highlight the risk of dependence on a single market. China's infant formula market is worth about US$25b, and the A2 protein segment is growing at 7 percent, but the top five brands hold 59 percent of the market, making competition intense. On supply, a2 is constrained by Synlait as its contract manufacturer; freight and customs problems caused stockouts, and consumers switched to competitors, showing that brand loyalty is fragile when products are unavailable.

The company has restored only 50 percent of shipments and kept distribution at two-thirds of previous levels, a sign of caution. On the other hand, emerging markets such as Vietnam grew 128 percent, but from too small a base to offset China risk in the short term. a2 is investing in the Pokeno plant transition, with $70m in capital expenditure aimed at controlling its supply chain, though near-term cost pressure is significant.

For New Zealand SMEs, the lesson is that businesses reliant on the China market need inventory buffers and diversified channels, while watching the competitive landscape in the A2 protein segment. a2's share price volatility and earnings decline show that even leading brands cannot fully avoid geopolitical and logistics risks.

Keywords: a2 Milk, China infant formula, revenue target, FY27 guidance, David Bortolussi, Synlait, Vietnam market, A2 protein, emerging markets, supply chain disruption


AI illustration on MiDeer Observer

Source: b2bnews.co.nz

Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.

Leave a Reply

Your email address will not be published. Required fields are marked *